Abcam (ABCZF) Asset Impairment Charge : $2.7 Mil (TTM As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Abcam Asset Impairment Charge?

Abcam's Asset Impairment Charge for the six months ended in Jun. 2023 was $2.7 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was $2.7 Mil.

Abcam Asset Impairment Charge Historical Data

The historical data trend for Abcam's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Asset Impairment Charge Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

Asset Impairment Charge

Get a 7-Day Free Trial

16.22

18.65

23.51

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	2.65

Abcam Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.7 Mil.

Abcam Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Abcam's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam (ABCZF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.